First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

BACKGROUND: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the efficacy and safety of bevacizumab plus XELOX, followed by bevacizumab plus capecita...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Feliu, J, Salud, A, Safont, M J, García-Girón, C, Aparicio, J, Vera, R, Serra, O, Casado, E, Jorge, M, Escudero, P, Bosch, C, Bohn, U, Pérez-Carrión, R, Carmona, A, Martínez-Marín, V, Maurel, J
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2014
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102952/
https://ncbi.nlm.nih.gov/pubmed/24946000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.346
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg